All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry.
The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit .
Allgemeine Beschreibung
ATRX (α-thalassemia/mental retardation syndrome X-linked) is encoded by the gene mapped to human chromosome Xq21.1. The encoded protein belongs to SWI/SNF (SWItch/sucrose non-fermentable) family of chromatin remodeling proteins.
Biochem/physiol Actions
ATRX (α-thalassemia/mental retardation syndrome X-linked) is involved in the H3.3-ATRX-DAXX chromatin-remodeling pathway. It plays a vital role in assimilation of the histone variant H3.3 at pericentric heterochromatin and at telomeres, as well as at several transcription factor binding sites. Mutation in the gene has been observed in various types of gliomas. Thus, this protein can be considered as a potential biomarker for gliomas. In addition, aberrations in the gene expression leads to characteristic developmental abnormalities, such as severe mental retardation, facial dysmorphism, urogenital abnormalities and α-thalassemia.
